Yale Cancer Center

Patricia M. LoRusso, DO, PhD (hc), has been elected president-elect of American Association for Cancer Research for 2023-2024.

Osimertinib extended DFS and reduced risk for recurrence among patients with resected EGFR-mutated non-small cell lung cancer, according to an updated analysis of data from the phase 3 ADAURA trial published in Journal of Clinical Oncology.

Today marks International Women’s Day.

SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.

SAN FRANCISCO — The addition of pembrolizumab to docetaxel failed to significantly extend survival for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 KEYNOTE-921 trial.

A recent study published in JAMA Oncology showed the use of aggressive cancer treatment at the end of life has not decreased but rather shifted from chemotherapy to immunotherapy.

Increased awareness of the quality-of-life harm and financial burden associated with continued cancer treatment at the end of a patient’s life has led professional societies to promote reduced systemic anticancer therapy at this stage.

American Association for Cancer Research and ASCO have issued a joint policy statement delineating the latest scientific evidence on use of e-cigarettes and other electronic nicotine delivery systems.

It was a cold Thursday night in November — the night of Thanksgiving 2022.

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, according to study findings.